I N T R O D U C T I O N
The major barrier to successful organ transplantation is prior sensitization of the recipient to donor human leukocyte antigens (HLA). Sensitization is reflected by the presence of donorspecific anti-HLA IgG antibodies (DSA) in recipient sera. Significant amounts of DSA indicate strong allosensitization and are commonly detected by the cell-based complementdependent cytotoxicity crossmatch (CDC-XM) assay. When positive, the risk of antibody-mediated rejection (AMR) and early graft loss is high, which is why a positive CDC-XM has long been considered a contraindication to transplantation [1] .
In an attempt to optimize pre-transplant risk stratification, solid-phase assays have been developed to detect DSA with increasing sensitivity and specificity [2] . Luminex-based analysis of patient sera using beads coated with single HLA-antigens (SAB) has revealed that patients with DSA detected only by SAB still carry a substantial risk of AMR and early graft loss despite a negative CDC-XM [3] [4] [5] . In recent years, SAB analysis has been increasingly used for organ allocation and, based on centre-specific algorithms, for the definition of unacceptable antigens [6, 7] and choice of induction therapy regimens [8] .
However, the predictive value of low-level DSA for the occurrence of AMR and graft loss in the individual patient is at best moderate [3, 8] and, therefore, attempts have been made to identify specific DSA properties, i.e. IgG subclass [9, 10] [11] [12] [13] , Fc glycosylation [14] , DSA strength [assessed by mean fluorescence intensity (MFI)] [3, 6] or dynamics of DSA levels post-transplantation [15, 16] , to segregate harmful from harmless DSA. Previous studies have been difficult to interpret due to heterogeneous patient populations analysed with respect to both immunological risk and induction regimens used [3, 6] . However, there seems to be consensus in the transplant community that all DSA-positive patients require depleting-antibody induction therapy [17] , although evidence for this strategy has been limited until now.
The aim of the present study was therefore to retrospectively analyse whether specific characteristics of DSA determined by solid-phase technology prior to transplantation can predict the risk of AMR and early graft loss in a homogenous cohort of patients treated with the same initial immunosuppressive regimen, but without depleting-antibody induction, to exclude a treatment-related bias on outcome.
M A T E R I A L S A N D M E T H O D S

Study population
From all patients that received a kidney transplant at our institution between January 2005 and December 2012, we retrospectively selected all those treated with an anti-IL-2-receptor-based induction therapy (basiliximab, Simulect V R , Roche, Basel, Switzerland) followed by a maintenance regimen consisting of a calcineurin inhibitor, mycophenolate mofetil and prednisolone (n ¼ 174, Table 1 ). Patients treated with depleting-antibody induction, i.e. anti-thymocyte globulins (ATG), or an mTOR-inhibitor-based maintenance regimen, were excluded as well as patients for whom no serum sample was available prior to transplantation. All patients were transplanted with a negative B-and T-lymphocyte CDC-XM using current sera. During the study period, SAB solid-phase assays were not routinely performed at our institution and hence had no influence on pre-transplant risk stratification and subsequent choice of induction therapy. Donor and recipient characteristics as well as clinical and histological data were obtained by careful chart review or were extracted from the Eurotransplant Network Information System. All retrospective analyses were performed with approval of the local Institutional Review Board.
Diagnosis of rejection and definition of AMR
All rejection episodes were biopsy-proven. Biopsies were obtained either as protocol biopsy on days 14 and 90 posttransplantation or when clinically indicated. Specimens were evaluated on light microscopy and immunofluorescence for C4d staining and were graded according to the BANFF 2007 classification [18] . C4d was considered positive upon focal or diffuse staining of peritubular capillaries. AMR was defined as C4d-positivity as defined above plus at least one of the following signs of parenchymal injury: glomerulitis, peritubular capillaritis, arteritis, thrombotic microangiopathy in glomeruli or otherwise unexplained acute tubular injury. If AMR was diagnosed together with T cell-mediated rejection (TCR), it was classified as AMR.
Detection and definition of DSA and donor HLA typing Sera taken at the time of kidney transplantation (all patients) as well as at 2 weeks, 6 and 12 months post-transplantation (patients with pre-transplant DSA) were retrospectively screened for the presence of anti-HLA class I and class II IgG antibodies. All sera were stored at À80 C. Screening was done using a commercial solid-phase microsphere-based assay on generic level (LSM12, One Lambda, Los Angeles, CA, USA). Sera were analysed on a LABScan 100 V R flow analyser (One Lambda), applying the manufacturer's recommended threshold ratio for positive results of 2.2. In positive sera, HLA specificity was determined by a single antigen assay for HLA class I and/or HLA class II antigens (LABScreen V R Single Antigen, One Lamba). The tests were performed according to the manufacturer's instructions applying a baseline-adjusted MFI cutoff for positive reactions of 500. Donor specificity of anti-HLA antibodies was defined based on the available donor HLA typing data. Donor HLA typing was performed according to standard Eurotransplant protocols. Typing for HLA-A, -B and -DR was done for all donors. DQ analysis was available in 161/174 (92.5%) and Cw analysis in 29/174 (16.7%) donors. DP typing was not routinely done and therefore anti-DP HLA antibodies were not evaluated for donor specificity. If donor specificity of anti-HLA antibodies could not be determined due to lack of high-resolution typing of a donor, they were classified as non-DSA. This occurred in 1 recipient for HLA class I and in 14 patients for HLA class II antibodies, respectively. As all these recipients had other DSA, lack of high-resolution typing of the donors had no impact on recipient categorization with respect to pre-transplant DSA status (not shown). In cases where Luminex analysis revealed the presence of antibodies for all different splits of an HLA antigen, the bead with the highest MFI was used for MFI categorization.
Statistical analysis
Statistical analysis was performed using IBM SPSS version 23.0 (SPSS Inc., Chicago, IL, USA). If not stated otherwise, data are presented as median (range). Continuous data were analysed depending on data distribution using Student's t-test for parametric and Wilcoxon rank sum test for nonparametric data. For categorical data, comparisons were based on the v 2 -test. All tests performed were two-sided. Survival analysis was performed by the Kaplan-Meier method and differences between groups were compared using the log-rank test. The association of DSA properties and traditional risk factors with AMR was analysed by univariate logistic regression. Significant risk factors in univariate analysis were then included in multivariable regression analysis. Risk factors for graft failure were determined using Cox regression. To identify independent predictors of graft loss, those variables identified as significant in bivariate analysis were included in multivariable analysis. Given the high correlation between median MFI of the highest individual DSA (MFI 
together in multivariable regression models. P < 0.05 was considered statistically significant.
R E S U L T S
Patient and treatment characteristics
Among the 174 CDC-XM-negative patients studied, 101 patients (58.0%) had circulating low-level anti-HLA IgG antibodies at the day of transplantation. In 61 patients (35.1% of the total population) anti-HLA IgG antibodies were donor specific (DSA). Baseline characteristics of the DSA-positive and the DSA-negative group are shown in Table 1 . We found several significant differences between the groups. DSA-positive patients had a higher rate of retransplantations, had higher current and historic CDC-panel reactive antibodies (PRA) and a higher proportion of deceased donors compared with the DSAnegative group. All patients received induction therapy with anti-IL-2 receptor blockade. Initial immunosuppression consisted of tacrolimus, mycophenolate mofetil and prednisolone in over 90% of patients. Two patients in the DSA-negative group received staurosporine instead of tacrolimus as part of a study protocol but were switched to tacrolimus within the first year post-transplantation and had an uneventful follow-up. Median follow-up was 6 years in the DSA-negative and 5.3 years in the DSA-positive group (P ¼ 0.02).
Characteristics of pre-transplant DSA
In total, 33/61 DSA-positive patients (54%) had one single DSA, 14 patients (23%) had two detectable DSA with the remaining 14 patients having three or more specificities; 21/61 (34.4%) had DSA against HLA class I, 20/61 (32.8%) against class II, with the remaining 20 patients being positive for DSA against both class I and II HLA. MFI max was 2945 (range 548-21 994), whereas the MFI cum was 3561 (range 548-61 261).
Kidney function
There was no significant difference in glomerular filtration rate (GFR) between DSA-positive and DSA-negative patients at 1, 3 or 5 years (not shown). Proteinuria was significantly higher at 3 and 5 years in DSA-positive compared with DSA-negative patients (median 219 versus 164 mg protein/g creatinine, P ¼ 0.045 and 286 versus 183, P ¼ 0.044, respectively).
Incidence of rejection
There was a high incidence of biopsy-proven acute rejection in both groups of patients with a trend toward more rejection episodes in DSA-positive compared with DSA-negative patients during the first year post-transplantation (37.7% versus 26.5%, P ¼ 0.13). This was driven by a significantly higher incidence of AMR in DSA-positive patients (19.7% versus 8.8%, P ¼ 0.04). The incidence of TCR was comparable (18.0% versus 17.7%, P ¼ 0.96, Table 2 ). AMR occurred mainly within the first year 
post-transplantation in both groups of patients (Supplementary Figure S1 ).
Patient and graft survival
During a median follow-up of 5.8 years, 11 patients died. Patient survival at 5 years was 94.8% and 95.4% in DSA-positive and DSA-negative patients, respectively (P ¼ 0.46). Deathcensored allograft survival was not statistically different between DSA-positive and DSA-negative patients (5-year allograft survival 82.9% versus 88.1%, respectively, P ¼ 0.46, Figure 1A) . Likewise, the presence of non-donor-specific HLA antibodies had no impact on allograft survival compared with DSApositive or Luminex-negative patients (5-year allograft survival 89.9, 82.9 and 87.2%, respectively, P ¼ 0.54 for overall comparison, Figure 1B) . 5-year allograft survival was poor in DSA-positive patients experiencing AMR (50.2%, Figure 1C ), whereas it was comparable to DSA-negative patients in the absence of AMR (91.1% versus 87.2%). When graft losses not attributable to alloimmunity were excluded from the analysis (Supplementary Table S1 ), there was a trend toward earlier graft loss in DSA-positive compared with DSA-negative patients (P ¼ 0.15, Supplementary Figure S2) . Figure S2A) . Proteinuria showed Figure S2B) .
Characteristics of pre-transplant
AMR. Univariate regression analysis revealed that patients positive for both class I and class II HLA-DSA had a significantly higher risk for early AMR compared with patients without DSA [odds ratio (OR) 8.55, P < 0.001], whereas the risk was not increased in patients with DSA against either HLA class I or HLA class II (Table 3) . When the strength of DSA assessed by either MFI max or MFI cum was analysed, we found a significantly higher risk for AMR in patients with an MFI max above 10 000 (OR 10.86, P < 0.001) or an MFI cum greater than 10 000 (OR 10.69, P < 0.001, Table 3 ). MFI max as well as MFI cum values above 3000 but below 10 000 were associated with an increased risk of AMR compared with DSA-negative patients, although this was not statistically significant ( Table 3 ). The simultaneous presence of DSA against HLA class I and II was highly correlated with high MFI max (Supplementary Table S2 ). In total, 7/10 patients with this pattern of DSA experienced early AMR. Univariate regression analysis confirmed that these patients had a particularly high risk for AMR compared with DSA-positive patients not fulfilling these criteria [OR 21.0, 95% confidence interval (95% CI) 4.33-101.83, P < 0.001]. Analysis of traditional risk factors revealed living donation to be protective and both current and historic PRA to confer a significantly higher risk of AMR in univariate analysis (Supplementary Table S3 ). In a model that included DSA class I and II and MFI max above 10 000, multivariable regression analysis revealed both DSA patterns to independently predict an increased risk for AMR (Table 4) .
Graft loss. Patients positive for both class I and class II HLA-DSA had a significantly worse allograft survival compared with DSA-negative patients (P ¼ 0.001, Figure 2A ). Of note, allograft survival was comparable between patients with DSA directed at either HLA class I or class II and patients without DSA. Cox regression analysis confirmed a significantly higher risk of graft failure only in patients with DSA against both HLA class I and II [hazard ratio (HR) 4.84, P ¼ 0.002, Table 5 ].
Stratification of graft survival using MFI revealed that both MFI max and MFI cum above 10 000 were associated with a significantly lower allograft survival compared with DSA-negative patients, whereas lower values were not (P ¼ 0.002 for MFI max , Figure 2B and P ¼ 0.001 for MFI cum , Figure 2C ). Accordingly, Cox regression analysis confirmed a higher risk for graft loss for DSA-positive patients with an MFI max above 10 000 (HR 5.19, P ¼ 0.009) or an MFI cum greater than 10 000 (HR 4.14, P ¼ 0.007, Table 5 ).
In total, 5/10 patients with simultaneous presence of DSA against HLA class I and II and an MFI max above 10 000 experienced graft loss during follow-up. This translated into a significantly lower allograft survival compared with DSA-positive patients not fulfilling these criteria (P < 0.001, Figure 2D) , as well as a significantly higher risk of graft loss by Cox regression analysis (HR 8.41, 95% CI 2.25-31.48, P ¼ 0.002). The risk for graft loss was significantly higher in patients experiencing AMR compared with patients who did not (HR 8.29, P < 0.001, Table 5 ). Living donation was protective in bivariate analysis (HR 0.35, P ¼ 0.04), whereas all other traditional risk factors tested had no significant impact on graft loss (Supplementary Table S4 ). Multivariable Cox regression analysis revealed AMR to be the only independent predictor of graft loss (HR 6.0, Table 4 ).
Dynamics of DSA post-transplantation and outcome. We next analysed sera from those 61 patients with detectable DSA prior to transplantation for the presence of DSA at 2 weeks as well as 3 and 12 months post-transplantation (Table 6 ). At 2 weeks post-transplantation, we observed a decrease in MFI cum in 51/61 (83.6%) patients. Among the 10 patients with higher MFI cum , 4 patients experienced early AMR whereas 6 patients were free from AMR during follow-up; 10/61 (16.4%) patients had at least one additional (de novo) DSA detectable 14 days post-transplantation. Among these patients, 6/10 experienced early AMR and 4 lost their graft during follow-up, resulting in worse allograft survival compared with patients without de novo DSA (P ¼ 0.09, Figure 3 ). Of note, 20/61 (32.8%) patients had undetectable DSA as early as 2 weeks post-transplantation and none of these patients experienced AMR or lost their graft during follow-up (Figure 3 ). Median MFI cum at baseline was significantly lower in these patients compared with patients who still had detectable DSA at 2 weeks (1517, range 548-6592 versus 9435, range 548-61261, P < 0.001). The same findings applied to the subgroup of patients with both class I and class II HLA-DSA prior to transplantation (Supplementary Figure S4) . 
One of the major findings of the present study was that the simultaneous presence of DSA against HLA class I and II prior to kidney transplantation was associated with an increased risk for AMR and early immunologically mediated graft loss. More importantly, however, patients considered to be at increased immunological risk due to the presence of either class I or class II HLA-DSA [3] [4] [5] had outcomes comparable to non-sensitized patients despite the fact that all patients received non-depleting induction therapy with basiliximab. These findings are in agreement with a previous report by Otten et al., who studied a large cohort of patients treated for the most part without any induction therapy and found lower graft survival compared with nonsensitized patients only in patients with DSA against both HLA class I and II [19] . We also found that high DSA strength (defined as MFI max of the highest individual DSA or cumulative MFI cum of all DSA above 10 000) correlated with a significantly increased risk for AMR and graft loss, whereas lower MFI cutoffs did not. Other studies have identified different cutoffs for either MFI max [19] [20] [21] [22] or MFI cum [6, 21] for segregation of patients at increased risk for AMR and graft loss from those without or have found a continuous increase in risk with increasing MFI [3, 20, 23] . The small number of patients with intermediate MFI in our study and subsequent low statistical power might in part explain why MFI max and MFI cum values below 10 000 were not associated with a significantly increased risk of AMR or graft loss. Therefore, larger studies will be needed to confirm these findings.
Using MFI as an approximation of antibody strength or titer has important limitations [2] . Besides inter-laboratory variability being an important confounder when comparing different studies, the prozone or hook effect and complement interference have to be considered [24] . All sera tested in our . In (D), allograft survival is shown for patients positive for class I and II DSA and MFI max above 10 000 (high risk) compared with DSA-positive patients not fulfilling these criteria (low risk). Allograft survival was censored for recipient death and graft loss not attributable to alloimmunity. study were heat-inactivated prior to analysis, largely abolishing complement interference [25] . As samples were not diluted, we cannot exclude a remaining prozone or hook effect as a reason for underestimating MFI in some of the patients, notably those with early AMR but negative SAB testing (see below). However, the low risk in patients with MFI below 3000 and the gradual increase in risk for AMR and graft loss with increasing MFI in our study strongly argue against a relevant role of these technical limitations on data interpretation. We observed a high rate of biopsy-proven acute rejection episodes in both DSA-positive (37.7%) and DSA-negative (26.5%) patients during the first year post-transplantation. This might be due to the fact that almost all patients underwent protocol biopsies at our centre and our analysis does not differentiate between clinical and subclinical rejection. Using a similar approach, Amico et al. reported rejection rates even above those reported here [4] . We also found a high incidence (8.8%) of early AMR in patients classified as DSA-negative prior to transplantation. In 6/12 patients, we found de novo DSA either prior to or at the time of AMR (data not shown); 3/12 patients were positive on Luminex testing prior to transplantation but could not be classified as having DSA due to incomplete donor typing. Importantly, two of these three patients likely had DSA using linkage analysis [26] for HLA-C and DQ based on available HLA-B and DR typing, respectively (data not shown). Screening for HLA antibodies was performed using the lesssensitive LSM test and only positive sera were further analysed using the single antigen assay. This approach, commonly used by HLA laboratories, has the potential limitation of not detecting some rare HLA specificities. However, in the three remaining patients with early AMR but a negative LSM test, reanalysis of pre-transplant sera using the single antigen assay confirmed the absence of DSA (data not shown).
Interpretation of previous work has been complicated not only by differences in patients' immunological risk between studies, but also by significant differences in both induction and maintenance therapy regimens used within individual studies. Whereas use of T cell-depleting agents has clearly resulted in a reduction of TCR in at-risk populations identified by conventional risk factors such as CDC-PRA above 30% or increased risk of delayed graft function [27] [28] [29] , the effect on the incidence of early AMR is less clear. B€ achler et al. compared the outcome of 37 CDC-XM-negative but DSA-positive patients treated with ATG and IVIG (intravenous immunoglobulins) induction with a historic control group of 67 DSA-positive patients of which 52% received basiliximab with the remaining not receiving any induction, and found a significant reduction in the incidence of AMR in those receiving ATG [30] . However, the historic control group had a higher degree of sensitization (higher MFI cum ) prior to transplantation and different maintenance immunosuppression, making interpretation of these findings difficult. In a recent study, Brokhof et al. found a lower incidence of de novo DSA and lower frequency of AMR in patients treated with ATG compared with basiliximab induction [31] . Concomitant use of plasmapheresis and IVIG in the ATG group again precludes final interpretation. Finally, in a recent report by Kannabhiran et al., neither ATG nor rituximab induction had a beneficial effect on the outcome of DSA-positive patients found to be at particularly high risk of AMR due to the presence of either MFI cum above 6000 or HLA class I and II DSA (Supplementary Table S6 in [6] ).
Despite a high incidence of early acute rejection in our study, 5-year allograft survival was good in the overall study cohort and comparable to studies with similar patient populations using depleting antibody induction [6, 8, 32] . Patients with isolated class I or II HLA-DSA and MFI max and MFI cum below 3000 had outcomes comparable to DSA-negative patients and should be able to be managed with basiliximab induction without significantly increasing the risk of early AMR and graft loss. Due to limited statistical power, the ideal immunosuppressive strategy in patients with intermediate MFI cannot be finally concluded from our data and should be studied in prospective, randomized, controlled trials. Finally, until new treatment strategies have proven efficacious in patients at particularly high risk for early AMR and graft loss, i.e. patients with simultaneous presence of DSA against HLA class I and II and/or high DSA strength [33] , it might be safer to preclude these patients from organ allocation and use the information on pre-transplant DSA characteristics for the definition of unacceptable HLA antigens. Lastly, monitoring DSA 14 days after transplantation is a very good prognostic indicator as patients that become DSA-negative early after transplantation have very good outcomes.
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